Table 3.
Intervention effects: baseline compared with mean of 3-, 6-, 9-, and 12-month scores.
| Outcome | Within-control | Within-CHESS+CMa | CHESS+CM – Control | ||
| Asthma control | |||||
| Symptom-free days odds ratiob | |||||
| Difference | 1.20 | 1.38 | 0.18 | ||
| 95% CLc | 0.98, 1.61 | 1.12, 1.71 | -0.88, 1.60 | ||
| P value | .29 | .01 | 1.00 | ||
| Asthma Control Questionnaired | |||||
| Differenced | –0.11 | –0.42 | –0.31 | ||
| 95% CL | –0.29, 0.07 | –0.60, –0.25 | –0.56, –0.06 | ||
| P value | .22 | .001b | .01 | ||
| Adherence | |||||
| Composite adherence scorese | |||||
| Difference | 0.58% | 2.06% | 1.48% | ||
| 95% CL | –6.24, 7.40 | –4.74, 8.86 | –8.15, 11.11 | ||
| P value | .87 | .55 | .76 | ||
| Pharmacy refill possession ratio | |||||
| Difference | 17.7% | 13.76% | –3.95% | ||
| 95% CL | 11.78, 23.62 | 7.83, 19.68 | –12.33, 4.43 | ||
| P value | .001b | .001b | .35 | ||
| Self-report controller 1: inhaled corticosteroidb | |||||
| Difference | –13.42% | –1.78% | 11.64% | ||
| 95% CL | –21.49, –5.35 | –18.67, –2.88 | –8.65, 13.93 | ||
| P value | .001b | .008 | .65 | ||
| Self-report controller 2: anticholingericsb | |||||
| Difference | –1.85% | 0.95% | 2.81% | ||
| 95% CL | –12.05, 8.34 | –8.73, 1.64 | –11.26, 16.87 | ||
| P value | .72 | .85 | .69 | ||
a Comprehensive Health Enhancement Support System plus monthly nurse case management.
b P< .01.
c Confidence limits.
d P ≤ .001.
e Sum of self-reported adherence data and pharmacy refill data.